Anemia Management in the China Dialysis Outcomes and Practice Patterns Study BLOOD PURIFICATION Zuo, L., Wang, M., Hou, F., Yan, Y., Chen, N., Qian, J., Wang, M., Bieber, B., Pisoni, R. L., Robinson, B. M., Anand, S. 2016; 42 (1): 33-43

Abstract

As the utilization of hemodialysis increases in China, it is critical to examine anemia management.Using data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS), we describe hemoglobin (Hgb) distribution and anemia-related therapies.Twenty one percent of China's DOPPS patients had Hgb <9 g/dl, compared with =10% in Japan and North America. A majority of medical directors targeted Hgb =11. Patients who were female, younger, or recently hospitalized had higher odds of Hgb <9; those with insurance coverage or on twice weekly dialysis had lower odds of Hgb <9. Iron use and erythropoietin-stimulating agents (ESAs) dose were modestly higher for patients with Hgb <9 compared with Hgb in the range 10-12.A large proportion of hemodialysis patients in China's DOPPS do not meet the expressed Hgb targets. Less frequent hemodialysis, patient financial contribution, and lack of a substantial increase in ESA dose at lower Hgb concentrations may partially explain this gap. Video Journal Club 'Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=442741.

View details for DOI 10.1159/000442741

View details for Web of Science ID 000377999600008

View details for PubMedID 27045519

View details for PubMedCentralID PMC4919113